Therapy Areas: Oncology
Regeneron and Sanofi to Improve Accessibility, Affordability of Praluent (alirocumab) for High-risk Cardiovascular Disease Patients
13 March 2018 - - Tarrytown, New York-based serious medical conditions treatment developer Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Paris, France-based human health-focused biopharmaceutical company Sanofi (EURONEXT: SAN) (NYSE: SNY) will offer a reduced net price for Praluent (alirocumab) Injection to payers that agree to reduce access barriers for high-risk patients, the company said.
The offer aligns with a new value assessment for high-risk patients from the Institute for Clinical and Economic Review (ICER), an independent organization that objectively evaluates the value of prescription drugs and other health care innovations.
The companies will take a precision medicine approach to address the burden of cardiovascular disease, focusing efforts on high-risk patients most vulnerable to future CV events, such as those who have suffered a previous coronary event and are unable to reduce their LDL cholesterol (LDL-C) below 100 mg/dL despite maximally-tolerated statin therapy.
In keeping with ICER's established "in confidence" procedures, Regeneron and Sanofi provided early access to data from the ODYSSEY OUTCOMES trial to enable a revised assessment of alirocumab value incorporating the ODYSSEY OUTCOMES results. ICER is
The companies will meet with health plans to discuss potential net pricing adjustments, and will work with cardiology healthcare professionals to define best practices in reducing barriers to access, in order to ensure that patients in need have their prescriptions filled quickly and efficiently.
Praluent inhibits the binding of PCSK9 (proprotein convertase subtilisin/kexin type 9) to the LDL receptor and thereby increases the number of available LDL receptors on the surface of liver cells, which lowers LDL-C levels in the blood.
Regeneron is a biotechnology company that invents medicines for patients with eye disease, heart disease, allergic and inflammatory diseases, pain, cancer, infectious diseases, and rare diseases.
Sanofi is dedicated to preventing illness with vaccines and to providing innovative treatments to fight pain and ease suffering, especially for people with rare diseases and those with long-term chronic conditions. The company has more than 100,000 people in 100 countries working to transform scientific innovation into healthcare solutions.


Related Headlines